|
RSF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.65280000025336E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.68919999999196E-05 |
| Normal-vs-Stage2 |
1.572170E-04 |
| Normal-vs-Stage3 |
2.66270000492952E-08 |
| Normal-vs-Stage4 |
1.53298999999718E-05 |
| Stage1-vs-Stage2 |
4.566800E-01 |
| Stage1-vs-Stage3 |
3.366300E-02 |
| Stage1-vs-Stage4 |
2.036600E-01 |
| Stage2-vs-Stage3 |
4.301000E-01 |
| Stage2-vs-Stage4 |
6.775400E-01 |
| Stage3-vs-Stage4 |
7.461200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.8368999994739E-07 |
| Normal-vs-AfricanAmerican |
1.320160E-01 |
| Normal-vs-Asian |
9.97889999999613E-05 |
| Caucasian-vs-AfricanAmerican |
1.101970E-01 |
| Caucasian-vs-Asian |
8.586800E-01 |
| AfricanAmerican-vs-Asian |
1.436040E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.01930000393236E-09 |
| Normal-vs-Female |
1.79434999999506E-05 |
| Male-vs-Female |
2.561600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.614500E-04 |
| Normal-vs-Age(41-60Yrs) |
5.77230000020634E-07 |
| Normal-vs-Age(61-80Yrs) |
2.81509999977558E-07 |
| Normal-vs-Age(81-100Yrs) |
1.040040E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.040850E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.479500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.108620E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.953800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.528800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.589200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.395930E-02 |
| Classical-VS-Follicular |
1.058050E-02 |
| Classical-VS-Other |
2.014800E-01 |
| Classical-VS-Normal |
8.07800000000025E-05 |
| Tall-VS-Follicular |
7.786000E-01 |
| Tall-VS-Other |
7.383000E-01 |
| Tall-VS-Normal |
1.22499999999359E-06 |
| Follicular-VS-Other |
7.035800E-01 |
| Follicular-VS-Normal |
7.14949999980341E-07 |
| Other-VS-Normal |
6.344800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.58620000023646E-07 |
| Normal-vs-N1 |
4.22620000000151E-05 |
| N0-vs-N1 |
8.021400E-01 |
|
|
